1681.HK 16

1681.HK CONSUN PHARMA

Healthcare · Drug Manufacturers - Specialty & Generic

9 · Strong Momentum 1.0 · Weak Safe

13.30

-0.23%

About the company

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. In addition, the company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules; and gastroenterology medicines, tonics, and other medicines. Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

6.02%
54.42%
0.80
11.2B
9.05
1.47
15.51

52-week range

13.3
low 12.3 high 19.4
Yield Growth Momentum Safety Value Health

Dividend deep dive

CONSUN PHARMA (1681.HK) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. The company currently offers a dividend yield of 5.86% in HKD, which sits below its 5-year average yield of 8.97%. The stock holds a strong overall rating of 9.0. It shows low price momentum with a score of 2.0 but indicates value with a score of 7.5.

Dividend history

The company currently has a dividend increase streak of 0 years. However, CONSUN PHARMA has demonstrated significant dividend growth, with a 3-year CAGR of 16.35% and a 5-year CAGR of 28.47%. Annual dividends per share in HKD include 0.0959 in 2014, 0.071 in 2015, 0.1411 in 2016, 0.196 in 2017, 0.20 in 2018, 0.30 in 2019, 0.18 in 2020, 0.30 in 2021, 0.40 in 2022, 0.45 in 2023, 0.90 in 2024, and 0.63 in 2025.

Dividend safety

CONSUN PHARMA's dividend is rated as 'safe'. The payout ratio stands at 54.42% of earnings. The company maintains healthy liquidity, with a current ratio of 3.219 and a quick ratio of 2.977.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

AI-generated from Quantic's dividend data · Updated 17 Aug 2026 · Information, not financial advice.

Price history

18.1 10.5 2.94 2021 2022 2023 2024 2025 2026 2020-07 · 3.28 2020-08 · 3.34 2020-09 · 3.05 2020-10 · 3.08 2020-11 · 3.09 2020-12 · 3.19 2021-01 · 3.27 2021-02 · 4.02 2021-03 · 4.60 2021-04 · 5.75 2021-05 · 5.07 2021-06 · 4.60 2021-07 · 3.67 2021-08 · 3.54 2021-09 · 3.36 2021-10 · 3.70 2021-11 · 4.40 2021-12 · 3.82 2022-01 · 3.72 2022-02 · 3.82 2022-03 · 4.63 2022-04 · 4.07 2022-05 · 4.18 2022-06 · 4.30 2022-07 · 4.03 2022-08 · 3.36 2022-09 · 2.94 2022-10 · 3.37 2022-11 · 4.05 2022-12 · 4.13 2023-01 · 4.45 2023-02 · 4.79 2023-03 · 5.09 2023-04 · 4.79 2023-05 · 5.30 2023-06 · 5.70 2023-07 · 5.18 2023-08 · 5.09 2023-09 · 4.60 2023-10 · 4.51 2023-11 · 4.77 2023-12 · 5.32 2024-01 · 5.68 2024-02 · 5.60 2024-03 · 5.85 2024-04 · 6.66 2024-05 · 5.56 2024-06 · 5.60 2024-07 · 5.72 2024-08 · 7.11 2024-09 · 8.27 2024-10 · 8.08 2024-11 · 8.13 2024-12 · 7.83 2025-01 · 8.00 2025-02 · 9.24 2025-03 · 9.26 2025-04 · 10.6 2025-05 · 11.3 2025-06 · 13.8 2025-07 · 14.9 2025-08 · 17.1 2025-09 · 15.0 2025-10 · 14.8 2025-11 · 15.6 2025-12 · 18.1 2026-01 · 18.0 2026-02 · 16.7 2026-03 · 16.2 2026-04 · 14.2 2026-05 · 12.6 2026-06 · 14.0 2026-07 · 14.2
Price

Dividend profile

Frequency
Semi-annual
Growth (TTM)
+21.7%
CAGR 3y
+16.3%
+28.5%
0 years

(5-year)

Now 6.0%
4.8% avg 9.0% 13.5%

Payment calendar

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Dividend history

CAGR 3y +16.3% CAGR 5y +28.5%
14 15 16 17 18 19 20 21 22 23 24 25

Per-share dividend by year

Quantic · Free

Unlock valuation & strategy

Two DDM fair values, margin of safety, sector value rank, Dividend Yield Theory, doubling time and max drawdown.

Debt & leverage

4.4%
3.22
2.98
Debt vs cash
Debt Cash
Total debt
212.9M HKD
Total cash
3.9B HKD
1.2B HKD

Latest reported balance-sheet figures.

Held by 2 investors

Appears in these lists

1681.HK qualifies for these curated dividend rankings.

Information, not financial advice.

Quantic · Free

Track 1681.HK and your whole portfolio

Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.

€0

Need more? Pro adds portfolios, options income tracking & more AI. See Pro →